Compare Amphastar Pharmaceuticals Inc (AMPH) vs American Water Works Company Inc (AWK) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

American Water Works (AWK) trades at $130.69, up 0.11% with a neutral technical outlook. The stock shows strong fundamentals with consistent revenue growth from $3.8B in 2022 to $5.1B in 2025, maintaining profit margins above 21%. Recent developments include infrastructure investments and regulatory approvals, while analyst consensus leans slightly bullish with a $137 price target.

AWK presents a stable investment opportunity with predictable utility earnings and dividend income. Key risks include regulatory rate approvals and capital expenditure requirements. The stock offers moderate upside potential with balanced analyst sentiment supporting long-term growth in essential water services.